Publications Real-world outcomes of advanced NSCLC patients with common and uncommon/complex EGFR mutation profiles September 8, 2019 Riely, GJ, Lovly, CM, Messina, CGM, Bienert, S, Alexander, K, Pao, W, Magee, K, Baxi, SS, Doebele, RC. World Conference on Lung Cancer. . Authors:Riely, GJ, Lovly, CM, Messina, CGM, Bienert, S, Alexander, K, Pao, W, Magee, K, Baxi, SS, Doebele, RC Sources:World Conference on Lung Cancer Read the research SharePosted inUnmet need More publicationsFebruary 2023Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration accelerated approvalJanuary 2022Using real-world evidence for label expansion: Use of palbociclib in male breast cancer patientsOctober 2020Organ dysfunction in advanced melanoma patients treated with immune checkpoint inhibitors
February 2023Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration accelerated approval
January 2022Using real-world evidence for label expansion: Use of palbociclib in male breast cancer patients
October 2020Organ dysfunction in advanced melanoma patients treated with immune checkpoint inhibitors